• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

    7/16/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QUCY alert in real time by email

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders.

    These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manufacturing of its autonomous defense platforms.

    About Quantum Drones Corporation

    Quantum Drones Corporation is a wholly owned Nevada-incorporated subsidiary of Quantum Cyber N.V. established to serve as the operational vehicle for the Company's domestic defense technology programs and U.S. government procurement activities. The subsidiary is led by Peter O'Rourke, President and Director, a former Acting Secretary of the U.S. Department of Veterans Affairs under the Trump administration, and Robert Liscouski, Director, a former Assistant Secretary for Infrastructure Protection at the U.S. Department of Homeland Security.

    About Quantum Cyber N.V.

    Quantum Cyber N.V. (NASDAQ:QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea. For more information, visit www.quantum-cyber.ai.

    Forward-Looking Statements

    Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements relate to, among other things, the; the reported purchase order and backlog figures for Arcade Metal Stamping and the reconciliation of duplicate order entries; the anticipated order backlog and forecasted demand from Arcade's customers, including Belimo and Rheem; the Company's expectations regarding future order volume over the next six months; and the integration of Arcade's operations into the Company's broader manufacturing strategy. Purchase order totals, backlog, and customer forecasts are based on order records and customer-provided planning data as of the dates indicated, are subject to change, cancellation, or rescheduling by customers, and do not guarantee future revenue; backlog figures reflect adjustments identified by the Company for duplicate entries in its order management system and remain subject to further review. The signing of a definitive agreement does not guarantee the consummation of the proposed transaction, and there can be no assurance that the transaction will close on the terms described or at all. These forward-looking statements reflect the Company's current analysis of existing information and are subject to various risks and uncertainties. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. Additional information concerning these and other factors may be found in the Company's filings with the SEC, including its Annual Report on Form 10-K filed on March 31, 2026, its Quarterly Report on Form 10-Q filed on May 15, 2026, and subsequent filings with the SEC. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.

    Investor Relations Contact:

    Arx Investor Relations

    North American Equities Desk

    qucy@arxhq.com



    Primary Logo

    Get the next $QUCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QUCY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QUCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that its wholly owned subsidiary, Quantum Drones Corporation, has completed the acquisition of certain parcels of real property located at 38 Union Avenue, Bridgeport, Connecticut, for a purchase price of $2,300,000. The transaction closed on July 15, 2026. The closing completes the real-property component of the Bridgeport acquisition that the Company first announced through a

    7/16/26 4:05:00 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders. These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manu

    7/16/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Completes Confidential Submission to U.S. Army Program

    WEST PALM BEACH, Florida, July 08, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has completed and submitted a confidential concept white paper and accompanying technical demonstration video to a technology program sponsored by a branch of the United States Army. The program is structured as a multi-phase, competitive down-select process open to select small and large businesses developing dual-use, autonomous capability for contested, distributed m

    7/8/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Buffalino Louis R. claimed no ownership of stock in the company (SEC Form 3)

    3 - Quantum Cyber N.V. (0001874252) (Issuer)

    7/9/26 5:00:21 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director O'Rourke Peter

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    7/7/26 6:02:30 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ben-Tzvi Avraham was granted 137,141 units of Ordinary Shares, increasing direct ownership by 6,857% to 139,141 units (SEC Form 4)

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    5/26/26 6:12:13 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    SEC Filings

    View All

    Mainz Biomed N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    7/16/26 4:05:26 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    7/1/26 4:05:20 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed N.V. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    6/26/26 5:00:15 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Leadership Updates

    Live Leadership Updates

    View All

    Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors

    WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu

    5/14/26 8:01:00 AM ET
    $NVAC
    $PFSA
    $QUCY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $QUCY
    Financials

    Live finance-specific insights

    View All

    Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders. These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manu

    7/16/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Completes Confidential Submission to U.S. Army Program

    WEST PALM BEACH, Florida, July 08, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has completed and submitted a confidential concept white paper and accompanying technical demonstration video to a technology program sponsored by a branch of the United States Army. The program is structured as a multi-phase, competitive down-select process open to select small and large businesses developing dual-use, autonomous capability for contested, distributed m

    7/8/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing Facility

    WEST PALM BEACH, Florida, July 06, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced projected production capacity targets for its proposed Bridgeport, Connecticut manufacturing facility, including an estimated annual output of approximately 100,000 drones upon completion of the facility and full operational modification and buildout. The production capacity targets are based on the Company’s current assessment of the facility’s manufacturing footprint and the

    7/6/26 8:00:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care